Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 5
2020 1
2021 4
2022 3
2023 2
2024 1
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta-Analysis.
Gorski D, Lazo REL, de Souza DA, Borba HHL, Pontarolo R, Tonin FS. Gorski D, et al. Pharmacotherapy. 2025 Sep;45(9):587-599. doi: 10.1002/phar.70049. Epub 2025 Aug 7. Pharmacotherapy. 2025. PMID: 40772520 Free PMC article.
Alongside infliximab 5 mg/kg (SUCRA 98.6%), 10 mg/kg (92%), and 20 mg/kg intravenous (91.8%), the recently approved drugs guselkumab 1200 mg (83.2%), 600 mg (89.2%), and 200 mg intravenous (90.1%), as well as mirikizumab 600 mg (91.5%) and 1000 mg intravenous (82.4%) presented hi …
Alongside infliximab 5 mg/kg (SUCRA 98.6%), 10 mg/kg (92%), and 20 mg/kg intravenous (91.8%), the recently approved drugs guselkumab 1200 mg …
Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy.
Linggi B, Filice M, Sangiorgi B, Smith MI, Teft W, Jairath V, Ma C, Vande Casteele N. Linggi B, et al. J Crohns Colitis. 2025 Jun 4;19(6):jjaf092. doi: 10.1093/ecco-jcc/jjaf092. J Crohns Colitis. 2025. PMID: 40488582 Free PMC article. Clinical Trial.
METHODS: Transcriptomics data from an andecaliximab phase 2/3 study in patients with UC were scored for gene signature enrichment. ...RESULTS: Of 11 gene sets, referred to as "Metabolism and Response to Stress" (MARS) signatures, 5 correlated with "non-disease" mucosa and …
METHODS: Transcriptomics data from an andecaliximab phase 2/3 study in patients with UC were scored for gene signature enrichment. .. …
Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets.
Bruschi A, Sambri A, Fiore M, Bubbico E, Scollo C, Pace A, Zunarelli R, Montanari A, Cappelli A, Di Prinzio L, De Paolis M. Bruschi A, et al. Cancer Med. 2025 May;14(9):e70901. doi: 10.1002/cam4.70901. Cancer Med. 2025. PMID: 40304052 Free PMC article. Review.
Moreover, batimastat, marimastat, tanomastat, andecaliximab, and HIV protease targeting MMPs; Volociximab/M200, cilengitide, abituzumab, and FAK inhibitors targeting integrins; LDN193189, DMH1, and ISLR modulators targeting BMPs; and PTH (7-33)-CBD targeting PTHrP have sho …
Moreover, batimastat, marimastat, tanomastat, andecaliximab, and HIV protease targeting MMPs; Volociximab/M200, cilengitide, abituzum …
Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co-expression network analysis.
Mortezapour M, Tapak L, Bahreini F, Najafi R, Afshar S. Mortezapour M, et al. Comput Biol Med. 2023 May;157:106779. doi: 10.1016/j.compbiomed.2023.106779. Epub 2023 Mar 11. Comput Biol Med. 2023. PMID: 36931200
Finally, results of the DGIDB database indicated that Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, and Bevacizumab, could be used as a therapeutic agent for targeting the MMP9. ...On …
Finally, results of the DGIDB database indicated that Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Inc …
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.
Yoshikawa AK, Yamaguchi K, Muro K, Takashima A, Ichimura T, Sakai D, Kadowaki S, Chin K, Kudo T, Mitani S, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Satoh T. Yoshikawa AK, et al. J Immunother Cancer. 2022 Jan;10(1):e003518. doi: 10.1136/jitc-2021-003518. J Immunother Cancer. 2022. PMID: 34992093 Free PMC article. Clinical Trial.
Cohort 1 enrolled patients with human epidermal growth factor receptor 2 (HER2)-negative tumors (n=8) who received andecaliximab monotherapy (800 mg by intravenous infusion every 2 weeks (Q2W)), and cohort 4 enrolled patients irrespective of their HER2 status (n=10) who re …
Cohort 1 enrolled patients with human epidermal growth factor receptor 2 (HER2)-negative tumors (n=8) who received andecaliximab mono …
Matrix metalloproteinases in the pathogenesis of dengue viral disease: Involvement of immune system and newer therapeutic strategies.
Niranjan R, Kishor S, Kumar A. Niranjan R, et al. J Med Virol. 2021 Aug;93(8):4629-4637. doi: 10.1002/jmv.26903. Epub 2021 Apr 6. J Med Virol. 2021. PMID: 33634515 Review.
The use of antibodies-based therapeutics like (Andecaliximab; anti-matrix metalloproteinase-9 antibody) is also suggested against MMPs in dengue. ...
The use of antibodies-based therapeutics like (Andecaliximab; anti-matrix metalloproteinase-9 antibody) is also suggested against MMP …
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Bendell J, Sharma S, Patel MR, Windsor KS, Wainberg ZA, Gordon M, Chaves J, Berlin J, Brachmann CB, Zavodovskaya M, Liu J, Thai D, Bhargava P, Shah MA, Khan SA, Starodub A. Bendell J, et al. Oncologist. 2020 Nov;25(11):954-962. doi: 10.1634/theoncologist.2020-0474. Epub 2020 Sep 17. Oncologist. 2020. PMID: 32812320 Free PMC article. Clinical Trial.
Median progression-free survival was 7.8 months (90% confidence interval, 6.9-11.0) with an objective response rate of 44.4% and median duration of response of 7.6 months. Maximal andecaliximab target binding, defined as undetectable, andecaliximab-free MMP9 in plas …
Median progression-free survival was 7.8 months (90% confidence interval, 6.9-11.0) with an objective response rate of 44.4% and median dura …
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Sandborn WJ, et al. J Crohns Colitis. 2018 Aug 29;12(9):1021-1029. doi: 10.1093/ecco-jcc/jjy049. J Crohns Colitis. 2018. PMID: 29767728 Free PMC article. Clinical Trial.
A phase 2/3 combined trial was designed to examine the efficacy, safety, and pharmacokinetics of the anti-MMP9 antibody, andecaliximab [formerly GS-5745], in patients with moderately to severely active UC. METHODS: Patients were randomised [1:1:1] to receive placebo, 150 m …
A phase 2/3 combined trial was designed to examine the efficacy, safety, and pharmacokinetics of the anti-MMP9 antibody, andecaliximab …
Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.
Espindola MS, Habiel DM, Coelho AL, Stripp B, Parks WC, Oldham J, Martinez FJ, Noth I, Lopez D, Mikels-Vigdal A, Smith V, Hogaboam CM. Espindola MS, et al. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. doi: 10.1164/rccm.201910-1977OC. Am J Respir Crit Care Med. 2021. PMID: 33052708 Free PMC article.
The inhibition of MMP9 activity with an anti-MMP9 antibody, andecaliximab, blocked TGF-beta1 (transforming growth factor beta1)-induced Smad2 phosphorylation. ...Further analysis of nonresponder ABC-like cells treated with andecaliximab revealed an association with …
The inhibition of MMP9 activity with an anti-MMP9 antibody, andecaliximab, blocked TGF-beta1 (transforming growth factor beta1)-induc …
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC. Shah MA, et al. Clin Cancer Res. 2018 Aug 15;24(16):3829-3837. doi: 10.1158/1078-0432.CCR-17-2469. Epub 2018 Apr 24. Clin Cancer Res. 2018. PMID: 29691300 Free PMC article. Clinical Trial.
Based on target engagement, recommended doses for further study are 800 mg q2w or 1,200 mg q3w. Maximal andecaliximab target binding, defined as undetectable andecaliximab-free MMP9 in plasma, was observed in the gastric/GEJ adenocarcinoma cohort. ...A phase III stu …
Based on target engagement, recommended doses for further study are 800 mg q2w or 1,200 mg q3w. Maximal andecaliximab target binding, …
19 results